Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, Phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial
J Am Acad Dermatol 2023;88:40–51. doi: 10.1016/j.jaad.2022.08.061
This Phase 3 study by Strober, et al. reports deucravacitinib superiority to placebo and apremilast in patients with PsO. The authors found that deucravacitinib had significantly higher rates of PASI 75 and sPGA achievement than placebo and deucravacitinib.